Advanced search
Publication Cover
Expert Opinion on Emerging Drugs Volume 10, 2005 - Issue 4
Submit an article Journal homepage
168
Views
36
CrossRef citations to date
0
Altmetric
Review

Current and emerging therapies for the lysosomal storage disorders

Gregory M Pastores New York University School of Medicine, Division of Neurogenetics, Departments of Neurology and Pediatrics, 403 East 34th Street, 2nd Floor, New York, NY 10016, USA. [email protected]
&
Natalie L Barnett New York University School of Medicine, Division of Neurogenetics, Departments of Neurology and Pediatrics, 403 East 34th Street, 2nd Floor, New York, NY 10016, USA. [email protected]
Pages 891-902 | Published online: 31 Oct 2005

Bibliography

  • VELLODI A: Lysosomal storage disorders. Br. J. Haematol. (2005) 128(4):L413–L431.
  • RAAS-ROTHSCHILD A, PANKOVA-KHOLMYANSKY I, KACHER Y, FUTERMAN AH: Glycosphingolipidoses: beyond the enzymatic defect. Glycoconj J. (2004) 21(6):295–304.
  • TSUJI D, KUROKI A, ISHIBASHI Y et al.: Specific induction of macrophage inflammatory protein 1-alpha in glial cells of Sandhoff disease model mice associated with accumulation of N-acetylhexosaminyl glycoconjugates. j Neurochem. (2005) 92(6):1497–1507.
  • Lysosomal disorders of the brain: recent advances in molecular and cellular pathogenesis and treatment. FM Platt, SU Walkley (Eds), Oxford University Press (2004).
  • GOKER-ALPAN O, HRUSKA KS, ORVISKY E et al.: Divergent phenotypes in Gaucher disease implicate the role of modifiers. J. Med. Genet. (2005) 42(6):e37.
  • MEIKLE PJ, RANIERI E, SIMONSEN H et al.: Newborn screening for lysosomal storage disorders: clinical evaluation of a two-tier strategy Pediatrics (2004) 114(0909–916.
  • LI Y, SCOTT CR, CHAMOLES NA et al.: Direct multiplex assay of lysosomal enzymes in dried blood spots for newborn screening. Clin. Chem. (2004) 50(10):1785–1796.
  • OSTRER H: A genetic profile of contemporary Jewish populations. Nat. Rev. Genet. (2001) 2(11):891–898.
  • KRIVIT W, SHAPIRO EG, PETERS C et al.: Hematopoietic stem-cell transplantation in globoid-cell leukodystrophy. N Engl. J. Med. (1998) 338(16):1119–1126.
  • RAMSAY SL, MAIRE I, BINDLOSS C et al.: Determination of oligosaccharides and glycolipids in amniotic fluid by electrospray ionisation tandem mass spectrometry: in utero indicators of lysosomal storage diseases. Mol. Genet. Metab. (2004) 83(3):231–238.
  • GOLD KF, PASTORES GM, BOTTEMAN MF et al.: Quality of life ofpatients with Fabry disease. Quell. Lift Res. (2002) 11(4):317–327.
  • MINERS AH, HOLMES A, SHERR L, JENKINSON C, MACDERMOT KD. Assessment of health-related quality-of-life in males with Anderson Fabry Disease before therapeutic intervention. Qual. Life Res. (2002) 11(2):127–133.
  • MACDERMOT KD, HOLMES A, MINERS AH: Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J. Med. Genet. (2001) 38(11):750–760.
  • MACDERMOT KD, HOLMES A, MINERS AH: Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J. Med. Genet. (2001) 38(11):769–775.
  • GRIENENBERGER A: Understanding orphan drug regulations: an EU and US comparative analysis. J. Biolaw Bus. (2004) 7(3):58–61.
  • ROJAS P: Genzyme finds the target. NASDAQ (2003):15–17.
  • PASTORES GM, MEERE PA: Musculoskeletal complications associated with lysosomal storage disorders: Gaucher disease and Hurler-Scheie syndrome (mucopolysaccharidosis type I). Curr. Opin. Rheumatol (2005) 17(1):70–78.
  • KLETA R, GAHL WA: Pharmacological treatment of nephropathic cystinosis with cysteamine. Expert Opin. Pharmacother. (2004) 5(11):2255–2262.
  • WINTERS JL, PINEDA AA, MCLEOD BC, GRIMA KM: Therapeutic apheresis in renal and metabolic diseases. Clin. Apheresis. (2000) 15(1-2):53–73.
  • SESSA A, MERONI M, BATTINI G et al.: Renal transplantation in patients with Fabry disease. Nephron (2002) 91(2):348–351.
  • CANTOR WJ, DALY P, IWANOCHKO M, CLARKE JT, CUSIMANO RJ, BUTANY J: Cardiac transplantation for Fabry's disease. Can. J. Cardiol (1998) 14(1):81–84.
  • KRIVIT W: Allogeneic stem cell transplantation for the treatment of lysosomal and peroxisomal metabolic diseases. Springer Semin. ImmunopathoL (2004) 26(1-2):119–132.
  • PETERS C, STEWARD CG; NATIONAL MARROW DONOR PROGRAM; INTERNATIONAL BONE MARROW TRANSPLANT REGISTRY; WORKING PARTY ON INBORN ERRORS; EUROPEAN BONE MARROW TRANSPLANT GROUP: Hematopoietic cell transplantation for inherited metabolic diseases: an overview of outcomes and practice guidelines. Bone Marrow Transplant. (2003) 31(4):229.
  • RINGDEN O, GROTH CG, ERIKSON A et al.: Ten years' experience of bone marrow transplantation for Gaucher disease. Transplantation (1995) 59:864–870.
  • KRIVIT W, SUNG JH, SHAPIRO EG, LOCKMAN LA: Microglia: the effector cell for reconstitution of the central nervous system following bone marrow transplantation for lysosomal and peroxisomal storage diseases. Cell Transplant. (1995) 4(4):385–392.
  • VELLODI A, YOUNG E, COOPER A, LIDCHI V, WINCHESTER B, WRAITH JE: Long-term follow-up following bone marrow transplantation for Hunter disease. J. Inherit. Metab. Dis. (1999) 22(5):638–648.
  • APPELBAUM FR: The current status of hematopoietic cell transplantation. Ann. Rev. Med. (2003) 54:491–512.
  • ESCOLAR ML, POE MD, PRO VENZALE JM et al.: Transplantation of umbilical-cord blood in babies with infantile Krabbe's disease. N Engl. J. Med. (2005) 352(20):2069–2081.
  • STABA SL, ESCOLAR ML, POE M et al.: Cord-blood transplants from unrelated donors in patients with Hurler's syndrome. N Engl. J. Med. (2004) 350(19):1960–1969.
  • PASTORES GM: Enzyme therapy for the lysosomal storage disorders: principles, patents, practice and prospects. Expert Opin. Ther. Patents (2003) 13(8):1157–1172.
  • SLY WS: Enzyme replacement therapy for lysosomal storage disorders: successful transition from concept to clinical practice. Mo/. Med. (2004) 101(2):100–104.
  • BRADY RO: Enzyme replacement therapy: conception, chaos and culmination. Philos. Trans. R. Soc. Lond. B. Biol. Sci. (2003) 358(1433):915–919.
  • ANDERSEN DC, KRUMMEN L: Recombinant protein expression for therapeutic applications. Curr. Opin. Biotechnol. (2002) 13(2):117–123.
  • SUZUKI K, EZOE T, TOHYAMA J, MATSUDA J, VANIER MT, SUZUKI K: Are animal models useful for understanding the pathophysiology of lysosomal storage disease? Acta Paediatr. SuppL (2003) 92(443):54–62.
  • WEINREB NJ, CHARROW J, ANDERSSON HC et al.: Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry. Am. J. Med. (2002) 113(2):112–119.
  • EAST L, ISACKE CM: The mannose receptor family. Biochim. Biophys. Acta. (2002) 1572(2-3):364–386.
  • CAMPBELL PE, HARRIS CM, VELLODI A: Deterioration of the auditory brainstem response in children with type 3 Gaucher disease. Neurology (2004) 63(2):385–387.
  • DOBBELAERE D, SUKNO S, DEFOORT-DHELLEMMES S et al.: Neurological outcome of a patient with Gaucher disease type III treated by enzymatic replacement therapy. J. Inherit. Metab. Dis. (1998) 21(1):74–76.
  • SCHIFFMANN R, KOPP JB, AUSTIN HA 3RD et al.: Enzyme replacement therapy in Fabry disease: a randomized controlled trial. /AMA. (2001) 285(21):2743–2749.
  • ENG CM, GUFFON N, WILCOX WR et al.: Safety and efficacy of recombinant human alpha-galactosidase A - replacement therapy in Fabry's disease. N EngL J. Med. (2001) 345(1):9–16.
  • PASTORES GM, THADHANI R: Advances in the management of Anderson-Fabry disease: enzyme replacement therapy. Expert Opin. Biol. Ther. (2002) 2(3):325–333.
  • MOORE DF, ALTARESCU G, HERSCOVITCH P et al.: Enzyme replacement reverses abnormal cerebrovascular responses in Fabry disease. BMC NeuroL (2002) 2(1):4.
  • WRAITH JE, CLARKE LA, BECK M et al.: Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase). j Pediatr. (2004) 144(5):581–588.
  • HARMATZ P, KETTERIDGE D, GIUGLIANI R et al.: Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): results after 48 weeks in a Phase II open-label clinical study of recombinant human N-acetylgalactosamine 4-sulfatase. Pediatrics (2005) 115(6):e681–e689.
  • PONCE E, MOSKOVITZ J, GRABOWSKI G: Enzyme therapy in Gaucher disease type 1: effect of neutralizing antibodies to acid beta-glucosidase. Blood (1997) 90(1):43–48.
  • ROSENBERG M, KINGMA W, FITZPATRICK Mk RICHARDS SM: Immunosurveillance of alglucerase enzyme therapy for Gaucher patients: induction of humoral tolerance in seroconverted patients after repeat administration. Blood (1999) 93(6):2081–2088.
  • HUNLEY TE, CORZO D, DUDEK M et al.: Nephrotic syndrome complicating alpha-glucosidase replacement therapy for Pompe disease. Pediatrics (2004) 114(4):e532–e535.
  • KLINGE L, STRAUB V NEUDORF U et al.: Safety and efficacy of recombinant acid alpha-glucosidase (rhGAA) in patients with classical infantile Pompe disease: results of a Phase II clinical trial. Neuromuscul. Disord. (2005) 15(1):24–31.
  • BUTTERS TD, DWEK RA, PLATT FM: New therapeutics for the treatment of glycosphingolipid lysosomal storage diseases. Adv. Exp. Med. Biol. (2003) 535:219–226.
  • MCCORMACK PL, GOA KL: Miglustat.Drugs (2003) 63(22):2427–2434.
  • ELSTEIN D, HOLLAK C, AERTS JM et al.: Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease. J. Inherit. Metab. Dis. (2004) 27(6):757–766.
  • PASTORES GM, BARNETT NL: Substrate reduction therapy: miglustat as a remedy for symptomatic patients with Gaucher disease type 1. Expert Opin. Investi g: Drugs (2003) 12(2):273–281.
  • PLATT FM, JEYAKUMAR M, ANDERSSON U et al.: Substrate reduction therapy in mouse models of the glycosphingolipidoses. Philos. Trans. R. Soc. Lond. B. Biol. Sci. (2003) 358(1433):947–954.
  • PROIA RL, WU YP: Blood to brain to the rescue. J. Clin. Invest. (2004) 113(8):1108–1110.
  • ABE A, WILD SR, LEE WL, SHAYMAN JA: Agents for the treatment of glycosphingolipid storage disorders. Curr. Drug Metab. (2001) 2(3):331–338.
  • DESNICK RJ: Enzyme replacement and enhancement therapies for lysosomal diseases. J. Inherit. Metab. Dis. (2004) 27(3):385–410.
  • MUCHOWSKI PJ, WACKER JL: Modulation of neurodegeneration by molecular chaperones. Nat. Rev. Neurosci. (2005) 6(1):11–22.
  • FRUSTACI A, CHIMENTI C, RICCI R et al.: Improvement in cardiac function in the cardiac variant of Fabry's disease with galactose-infusion therapy. N Engl. J. Med. (2001) 345(1):25–32.
  • SAWKAR AR, CHENG WC, BEUTLER E et al.: Chemical chaperones increase the cellular activity of N370S beta-glucosidase: a therapeutic strategy for Gaucher disease. Proc. Nail. Acad. Sci. USA (2002) 99(24):15428–15433.
  • MATSUDA J, SUZUKI O, OSHIMA A et al.: Chemical chaperone therapy for brain pathology in G(M1)-gangliosidosis. Proc. Natl. Acad. Sci. USA (2003) 100(261:15912–15917.
  • TROPAK MB, REID SP, GUIRAL M, WITHERS SG, MAHURAN D: Pharmacological enhancement of beta-hexosaminidase activity in fibroblasts from adult Tay-Sachs and Sandhoff Patients. J. Biol Chem. (2004) 279(1013478–13487.
  • YAM GH, ZUBER C, ROTH J: A synthetic chaperone corrects the trafficking defect and disease phenotype in a protein misfolding disorder. FASEB J. (2005) 19(1):12–18.
  • WHITTINGTON R, GOA KL: Alglucerase. A pharmacoeconomic appraisal of its use in the treatment of Gaucher's disease. Pharmacoeconomics (1995) 7(1):63–90.
  • CLARKE JT, AMATO D, DEBER RB. Managing public payment for high-cost, high-benefit treatment: enzyme replacement therapy for Gaucher's disease in Ontario. CMAJ (2001) 165(5):595–596.
  • POENARU L: From gene transfer to genetherapy in lysosomal storage diseases affecting the central nervous system. Ann. Med. (2001) 33(1):28–36.
  • IOANNOU YA, ENRIQUEZ A. BENJAMIN C: Gene therapy for lysosomal storage disorders. Expert Opin. Biol. Ther. (2003) 3(5):789–801.
  • VITE CH, MCGOWAN JC, NIOGI SN, PASSINI MA, DROBATZ KJ, HASKINS ME, WOLFE JH. Effective gene therapy for an inherited CNS disease in a large animal model. Ann. NeuroL (2005) 57(3):355–364.
  • CONSIGLIO A, QUATTRINI A. MARTINO S et al.: In vivo gene therapy of metachromatic leukodystrophy by lentiviral vectors: correction of neuropathology and protection against learning impairments in affected mice. Nat. Med. (2001) 7(3):310–316.
  • MATZNER U, SCHESTAG F, HARTMANN D et al.: Bone marrow stem cell gene therapy of arylsulfatase A-deficient mice, using an arylsulfatase A mutant that is hypersecreted from retrovirally transduced donor-type cells. Hum. Gene Ther. (2001) 12(9):1021–1033.
  • BIFFI A, DE PALMA M, QUATTRINI A et al.: Correction of metachromatic leukodystrophy in the mouse model by transplantation of genetically modified hematopoietic stem cells. J. Clin. Invest. (2004) 113(8):1118–1129.
  • MARTIN-TOUAUX E, PUECH JP, CHATEAU D et al.: Muscle as a putative producer of acid alpha-glucosidase for glycogenosis type II gene therapy. Hum. MoL Genet. (2002) 11(14):1637–1645.
  • BARRANGER JM, NOVELLI EA: Genetherapy for lysosomal storage disorders. Expert Opin. Biol. Ther. (2001) (5):857–867.
  • SONDHI NR, HACKETT RL, APBLETT SM et al.: Feasibility of gene therapy for late neuronal ceroid lipofuscinosis. Arch. NeuroL (2001) 58:1793–1798.
  • KOZUTSUMI Y, KANAZAWA T, SUN Y et al.: Sphingolipids involved in the induction of multinuclear cell formation. Biochim. Biophys. Acta. (2002) 1582(1-3):138–143.
  • BEGLEY DJ: Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. Pharmacol Ther. (2004) 104(1):29–45.
  • ELSEA SH, LUCAS RE: The mousetrap: what we can learn when the mouse model does not mimic the human disease. ILAR J. (2002) 43(2):66–79.
  • JEYAKUMAR M, SMITH DA, -WILLIAMS IM et al.: NSAIDs increase survival in the Sandhoff disease mouse: synergy with N-butyldeoxynojirimycin. Ann. Neurol. (2004) 56(5):642–649.

Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.